Feb

2010

Altair Therapeutics, Inc.: Series B $17M

Posted in I - Series B, Q - 4Q09, R - WEST, X - Asthma, X - Respiratory, X - Rhinitis, XX - CA

Altair Therapeutics (San Diego, CA) a clinical-stage biopharmaceutical company focused on antisense therapeutics for asthma and rhinitis, closed a $17M Series B financing. Participants include Domain Associates, AgeChem Venture Fund, Thomas McNerney & Partners and Forward Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

MobileMD, Inc.: Series A $4.7M

Posted in I - Series A, Q - 4Q09, R - NORTH EAST, X - TeleMedicine, XX - PA

MobileMD (Warminster, PA) a commercial-stage electronic medical records information exchange and clinical data repository platform, closed a $4.7M Series A financing. Participants include Health Enterprise Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Ortho Kinematics, Inc.: Series A $2.0M

Posted in I - Series A, Q - 4Q09, R - SOUTH WEST, X - Device (Diagnostic), X - Device (Spine), XX - TX

Ortho Kinematics (Austin, TX) a development-stage spine diagnostics company focused on inter-vertebral motion analysis, closed a $2M Series A financing. Participants include PTV Sciences, Texas Emerging Technology Fund and Gatebridge Investments.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

SantoSolve, AS: Series C $5.5M

Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Analgesic, X - Pain

SantoSolve (Norway) a clinical-stage biopharmaceutical company focused on topical analgesic products based on non-radioactive strontium for various pain conditions, closed a $5.5M Series C financing. Participants include Teknoinvest, InnovationsKapital and Investinor.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Kreatech Diagnostics, BV: Series B $2.7M

Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Device (Diagnostic)

Kreatech Diagnostics (Netherlands) a commercial-stage molecular diagnostics company focused on DNA FISH probes and nucleic acid labeling technologies, closed a $2.7M Series B financing. Participants include Alafi Capital and Life Science Partners.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Terapio Corp.: Series A $5M

Posted in I - Series A, Q - 4Q09, R - SOUTH WEST, X - Radiodermatitis, X - THx Delivery

Terapio (Austin, TX) a preclinical-stage biopharmaceutical company focused on radiodermatitis, closed a $5M Series A financing. Participants have included Santé Ventures and Texas Emerging Technology Fund.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Receptos, Inc.: Series A $25M

Posted in I - Series A, Q - 4Q09, R - WEST, X - Autoimmune, X - GPCR, X - Immunology, XX - CA

Receptos (San Diego, CA) a preclinical stage biopharmaceutical company focused on structural biolog GPCR approaches targeting autoimmune disease, closed a $25M Series A financing. Participants include ARCH Venture Partners, Flagship Ventures, Lilly Ventures and Venrock.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Ligon Discovery, Inc.: Series A $1M

Posted in I - Series A, Q - 4Q09, R - NORTH EAST, X - Device (HTS), X - Device (Microarray), XX - MA

Ligon Discovery (Cambridge, MA) a development-stage HTS drug-discovery platform employing Small Molecule Microarray technology, closed a $1M seed financing. Participants include incTank Ventures.
Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Cellerix, SL: Series C $37.7M

Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Crohn's, X - GI, X - Stem Cell

Cellerix (Spain) a clinical-stage biopharma company focused on adult stem cell therapies for Crohn’s and other GI diseases, closed a $37.7M Series C financing. Participants include Ysios Capital Partners, Ventech, Roche Venture Fund and Novartis Venture Fund.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

BioVex, Inc.: Series F $30M

Posted in I - Series F, Q - 4Q09, R - NORTH EAST, X - Biologics Mfg., X - Oncology, XX - MA

BioVex (Woburn, MA) a clinical-stage biologics company focused on metastatic melanoma, head and neck, pancreatic and colo-rectal cancer, closed a $30M Series F bringing the entire round to $70M. Participants have included Morningside Venture, Ventech, MVM Life Science Partners, Sectoral Asset Management, Ysios Capital Partners, Forbion Capital Partners, Credit Agricole Private Equity, Harris & Harris [...]

Jan

2010

Elara Pharmaceuticals, GmbH: Series A $3.6M

Posted in I - Series A, Q - 4Q09, R - INTERNATIONAL, X - HIF, X - Oncology

Elara Pharmaceuticals (Germany) a preclinical-stag biopharma focused on Hypoxia Inducible Factor antagonizing drugs for the treatment of different cancers, closed a $3.6M Series A financing. Participants include EMBL Ventures.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

Jan

2010

Oxagen, Ltd.: Series C $25.9M

Posted in I - Series C, Q - 4Q09, R - INTERNATIONAL, X - Asthma, X - Inflammation, X - Respiratory, X - Rhinitis

Oxagen (United Kingdom) a clinical-stage biopharmaceutical company focused on asthma and allergic rhinitis based drug company focused on inflammation, closed a $25.M Series C financing. Participants include MPM Capital, SV Life Sciences, Advent Ventures, Bessemer Venture Partners, Omega Ventures, Abingworth, International Bio Trust, Red Abbey Venture Partners and Wellcome Trust.

Note: 2009 Year-in-Review Trend Analysis Coming [...]

Jan

2010

Xigen, SA: Series B $20M

Posted in I - Series B, Q - 4Q09, R - INTERNATIONAL, X - Cardiology, X - Inflammation

Xigen (Switzerland) a clinical-stage biopharma company focused on Jun Kinase inhibitor for stroke, inflammation and hearing loss, closed a $20M Series B financing. Participants have included Tilocor Life Sciences, VI Partners and DEFI Gestion.

Note: 2009 Year-in-Review Trend Analysis Coming 15 Feb

« Previous Entries Next Entries »

to top of page...